Case report demonstrates blinatumomab achieves remission in Ph+ ALL and CLL, suggesting new treatment potential.
CD19 directed immunotherapy with monoclonal antibodies and chimeric antigen receptor T (CAR-T) cell therapy has shown treatment efficacy in the relapsed/refractory setting for non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). However, the CD19 directed bispecific T-cell engager, blinatumomab, is currently only approved in B-cell acute lymphoblastic leukemia (ALL) and it has largely not been investigated in other clinical contexts for CLL. We report a case of a patient who presented with both Philadelphia chromosome positive (Ph+) ALL and CLL who achieved measurable residual disease (MRD) negative remission for both diseases with blinatumomab.
No takes yet. Share an insight, caveat, or question.
Darwish et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: